Chrysomycin A was first isolated from the Streptomyces A-419 strain in 1955 as a mixture of chloramphenicol A and B, and is considered one of the most promising candidates for the treatment of infections caused by multidrug-resistant Gram-positive bacteria. Strain 891, isolated from sediments in the South China Sea, has been found to yield the highest concentration of Chrysomycin A (3,600 mg/L) of all known strains under optimal conditions.
Chrysomycin A is the major analogue in a complex of C-glycoside antitumor actives isolated from Streptomyces. Chrysomycin A, with a vinyl group in the 8-position, is the most potent analogue of the complex, and is thought to act as an inhibitor of the catalytic activity of human topoisomerase II. Chrysomycin A has a potent antibacterial, antifungal, antiviral and antitumor profile. More recent research on related metabolites, the gilvocarcins, suggests that chrysomycins may act as photoactivated cross-linkers of DNA to histones.
Chrysomycin A is a potent antibacterial, antifungal and antiviral compound.
ChEBI: Chrysomycin a is a glycoside.
